Presentations

The T Cell Engineering Lab research team regularly presents its research at annual conferences held by the American Society of Hematology, the European Hematology Association, the National Comprehensive Cancer Network, and the American Society of Transplantation and Cellular Therapy.

Past presentations by the T Cell Engineering Lab research team include:

62nd ASH Annual Meeting and Exposition

• Virtual
• Dec. 11-14, 2020

• ZUMA-19: A phase 1/2 multicenter study of lenzilumab use with axicabtagene ciloleucel (Axi‑Cel) in patients (Pts) with relapsed or refractory large B Cell lymphoma (R/R LBCL)
• Axl-RTK inhibition modulates monocyte immune response to enhance the anti-tumor effects of CD19 redirected chimeric antigen receptor T cells in preclinical models
• Vesicular stomatitis virus (VSV) engineered to express CD19 stimulates anti-CD19 chimeric antigen receptor modified T cells and promotes their anti-tumor effects
• Efficient gene editing of CAR-T cells with CRISPR-Cas12a for enhanced antitumor efficacy

Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

• Orlando, Florida
• Feb. 19-23, 2020

• Circulating extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia (CLL)
• Development of a sensitive and efficient reporter platform for the detection of chimeric antigen receptor T cell expansion, trafficking, and toxicity
• Improved anti-tumor response of chimeric antigen receptor T Cell (CART) therapy after GM-CSF inhibition is mechanistically supported by a novel direct interaction of GM-CSF with activated carts
• Targeting cancer associated fibroblasts in the bone marrow prevents resistance to chimeric antigen receptor T cell therapy in multiple myeloma
• Targeting of CD19 by tafasitamab does not impair CD19 directed chimeric antigen receptor T cell activity in vitro

61st ASH Annual Meeting and Exposition

• Orlando, Florida
• Dec. 7-10, 2019

• Circulating extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia (CLL)
• Development of a sensitive and efficient reporter platform for the detection of chimeric antigen receptor T cell expansion, trafficking, and toxicity
• Improved anti-tumor response of chimeric antigen receptor T Cell (CART) therapy after GM-CSF inhibition is mechanistically supported by a novel direct interaction of GM-CSF with activated carts
• Targeting cancer associated fibroblasts in the bone marrow prevents resistance to chimeric antigen receptor T cell therapy in multiple myeloma
• Targeting of CD19 by tafasitamab does not impair CD19 directed chimeric antigen receptor T cell activity in vitro

European Hematology Association

• Amsterdam, Netherlands
• June 15, 2019

• Axl-RTK inhibition directs the functional phenotype of chimeric antigen receptor T cells.

National Comprehensive Cancer Network 24th Annual Conference

• Orlando, Florida
• March 21-23, 2019

• Axl-RTK inhibition modulates T cell functions and synergizes with chimeric antigen receptor t cell therapy in B cell malignancies
• Size matters: Larger size CD19-positive extracellular vesicles in chronic lymphocytic leukemia (CLL) inhibit chimeric antigen receptor T-cell function

Transplantation and Cellular Therapy Meetings

• Houston, Texas
• Feb. 20-24, 2019

• Axl-RTK inhibition modulates T cell functions and synergizes with chimeric antigen receptor T cell therapy in B cell malignancies
• GM-CSF blockade during chimeric antigen receptor T-Cell (CART) therapy reduces cytokine release syndrome and neurotoxicity and may enhance CART effector functions